Compassionate Use of REGN-COV2 for the Treatment of COVID-19
NCT04617535 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-10-03
Summary
Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.
Conditions
Interventions
- DRUG
-
REGN10933+REGN10987 combination therapy
Administered intravenously (IV) single dose
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Convalescent Plasma in the Treatment of COVID 19
NCT04343261 ·Status: COMPLETED ·Phase: PHASE2
-
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
NCT05235347 ·Status: NO_LONGER_AVAILABLE
-
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
NCT06063330 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Convalescent Plasma for COVID-19
NCT04408040 ·Status: TERMINATED ·Phase: PHASE2
-
Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study
NCT04669990 ·Status: UNKNOWN
-
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
NCT04287686 ·Status: WITHDRAWN ·Phase: NA
-
DEFINE - Evaluating Therapies for COVID-19
NCT04473053 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
NCT04438057 ·Status: COMPLETED ·Phase: PHASE2
-
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
NCT04435015 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392232 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
NCT04502472 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
NCT04390178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04445207 ·Status: NO_LONGER_AVAILABLE
-
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
NCT04343755 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486 ·Status: NO_LONGER_AVAILABLE
-
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
NCT04321993 ·Status: UNKNOWN ·Phase: PHASE2
-
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
NCT04323761 ·Status: APPROVED_FOR_MARKETING
-
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
NCT04349410 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Defibrotide for the Treatment of Severe COVID-19
NCT04652115 ·Status: RECRUITING ·Phase: PHASE2
-
Novel Experimental COVID-19 Therapies Affecting Host Response
NCT04924660 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immune Modulators for Treating COVID-19
NCT04593940 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
NCT04335136 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma
NCT04340050 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Convalescent Plasma Therapy - Zurich Protocol
NCT04869072 ·Status: COMPLETED ·Phase: PHASE1